New drug duo takes on tough blood cancers

NCT ID NCT05986240

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a drug called danvatirsen, first by itself and then combined with venetoclax, in 38 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if the treatment is safe and can shrink or control the cancer. Because it's a Phase 1 trial, the main focus is on safety and finding the right dose, not yet on proving it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Danvatirsen and venetoclax
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat AML or MDS.
What could go wrong: This is a very early Phase 1 trial with only 38 participants, so it may not show strong benefit or could have unexpected side effects. Success in this small group may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome Myelodysplastic Syndromes therapy related acute myeloid leukemia and myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA AML/MDS MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

M.D. Anderson Cancer Center, Department of Leukemia
RECRUITING

Houston, Texas, 77030, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.